We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.80 | 0.80 | 0.80 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/7/2021 12:23 | If not him then someone is happy to add in 100k and 250k chunks at full on Bid, +ve afternoon ahead. GLA | tburns | |
16/7/2021 12:06 | Looks like John Kight is adding to his already large holding from recent trades | tburns | |
16/7/2021 10:53 | That's a worry!! | peanut100 | |
16/7/2021 10:45 | FinnCap is the best small cap broker of 2021 peanut. See here: | on target | |
16/7/2021 10:26 | It's time for a new broker - Numis or Liberum for me. | peanut100 | |
15/7/2021 22:11 | on target, considering the price movement over the last 12 months, not holding this stock for long seems a very sensible approach. | kingalf | |
15/7/2021 13:17 | Short-term 'traders' i.e. those that can't hold onto a stock for more than a day or two would have bought yesterday or Friday and are now ditching it to chase another rainbow. | on target | |
15/7/2021 13:07 | Buyers coming in now. Yes there seems to be a lot of 'tree shaking' going on across the board. Small PIs being worried-out to the advantage of the bigger boys. | on target | |
15/7/2021 12:14 | I am puzzled with the price action here. I really thought we would at least leave 5p behind after those recent RNS's. Maybe the market wants to see if Huw et al are going to be buying, before committing funds/further funds themselves. I know I am now. | lovewinshatelosses | |
15/7/2021 10:56 | Games continue ... I've emailed house broker... asked them, what's going on with SPand what are you earning your corn for !! | amaretto1 | |
14/7/2021 14:09 | I see that MonkeyMunch has gone over to UKOG bb (his previous ramping grounds) to do some ramping there, having failed over here? He was last ramping UKOG at 11.00p a share, and he has now started ramping UKOG at 0.17 a share! What an 1D10T !!! Now for his outburst! 🤣 🤣 🤣 ! | jack4691 | |
14/7/2021 10:27 | James Robert Kight now up to 4% - | tomboyb | |
13/7/2021 21:54 | Happy with the newsflow today and good to see a new large holder come on board. Hopefully sticky hands. Might buy more myself if we see decent inside buying shortly. Might anyway, to be honest! GLA. | lovewinshatelosses | |
13/7/2021 19:47 | Maybe will buy tomorrow now AGM out the way | peanut100 | |
13/7/2021 19:33 | Director's buys, first thing tomorrow maybe | tburns | |
13/7/2021 18:56 | Why not release this last bit of news first thing tomorrow.... | peanut100 | |
13/7/2021 18:04 | "Extremely well funded" clocktower...Gl ;-) 9/7/21 "The Company mounted a rapid and important response to the current pandemic advised by colleagues in Dundee. From our point of view, the programme was always opportunistic and driven by urgent clinical need. The financial contribution from Evgen was not significant and we reiterate that our core programmes remain oncology focused. Complementing our positive phase 2 clinical data in metastatic breast cancer we have recently reported further positive data in cells derived from patients who had developed resistance to the widely used class of CDK4/6 inhibitors. We have also recently reported compelling data in pre-clinical models in glioblastoma from two academic centres. The Company is extremely well funded and we look forward to updating the market further as our oncology data sets strengthen and will continue to pursue attractive commercial opportunities for SFX-01." | moneymunch |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions